May 3rd 2024
Robert Den, MD, and Alpha Tau are seeking motivated investigators who may be interested in participating in the trial.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
A review of treatment for dermatofibrosarcoma
September 17th 2018Dermatofibrosarcoma is a common, but unusual locally aggressive cutaneous tumor. Its characteristic tentacle can grow into surrounding fat, muscle and even bone. For dermatologists this means that understanding treatment options is a priority, says a physician reporting from EADV 2018.
Surgical treatment for basal cell carcinomas still the best bet
September 17th 2018There are many non-surgical treatments for basal cell carcinomas, but a physician reporting at EADV last week said new treatments should be compared against surgery, which has the highest cure rate and lowest rate of recurrence.
Treating moles and melanoma during pregnancy
September 17th 2018A pregnancy-associated melanoma (PAM) prognosis does not appear to be worse than melanoma in non-pregnant controls, researchers reported at EADV. Nonetheless, measures should be taken to protect the fetus in the treatment and imaging of PAM.
Advent of immunotherapy may require a new, expanded role for dermatologists
September 14th 2018With immunotherapy as a key treatment for melanoma, dermatologists should be prepared to treat its cutaneous side effects and refer for adrenal sufficiency, uveitis, thyroid disease and other non-cutaneous side effects.
EADV report highlights the future of checkpoint inhibitors in advanced melanoma
September 14th 2018Checkpoint inhibitors have clearly changed the prognosis of melanoma, yet the search for evidence-based answers to these and other questions regarding their use continues, experts report at EADV this week.
It may be time to update the melanoma staging system, researchers report
June 11th 2018Researchers reporting at the American Society of Clinical Oncology annual meeting on June 4 presented a study in which they compared the seventh and eighth editions of the American Joint Committee on Cancer melanoma staging systems. The eighth edition differentiates melanoma survival slightly worse than the previous edition.